Enteric-coated Mycophenolate sodium (EC-MPS), valsartan

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

De Novo Renal Transplantation

Conditions

De Novo Renal Transplantation

Trial Timeline

Oct 1, 2002 → Jun 1, 2005

NCT ID

NCT00308425

About Enteric-coated Mycophenolate sodium (EC-MPS), valsartan

Enteric-coated Mycophenolate sodium (EC-MPS), valsartan is a phase 3 stage product being developed by Novartis for De Novo Renal Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT00308425. Target conditions include De Novo Renal Transplantation.

What happened to similar drugs?

9 of 15 similar drugs in De Novo Renal Transplantation were approved

Approved (9) Terminated (1) Active (5)

✅Tacrolimus targeted half-dose + Tacrolimus targeted plain doseAstellas PharmaApproved

✅Prograf + AdvagrafAstellas PharmaApproved

✅ATG-FAstellas PharmaApproved

✅Advagraf + Prograf + Corticosteroid + Mycophenolate mofetilAstellas PharmaApproved

✅Tacrolimus targeted half-dose + Tacrolimus targeted plain doseAstellas PharmaApproved

✅Enteric-coated Mycophenolate sodium (EC-MPS)NovartisApproved

✅Enteric-Coated Mycophenolate Sodium (EC-MPS)NovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00308425	Phase 3	Completed	Oct 1, 2002	Jun 1, 2005	De Novo Renal Transplantation

Competing Products

19 competing products in De Novo Renal Transplantation

See all competitors

Product	Company	Stage	Hype Score
Alefacept + placebo + Tacrolimus + Mycophenolate Mofetil + Steroids	Astellas Pharma	Phase 2	35
Tacrolimus targeted half-dose + Tacrolimus targeted plain dose	Astellas Pharma	Approved	39
Prograf + Advagraf	Astellas Pharma	Approved	43
ATG-F	Astellas Pharma	Approved	43
Advagraf + Prograf + Corticosteroid + Mycophenolate mofetil	Astellas Pharma	Approved	43
Tacrolimus targeted half-dose + Tacrolimus targeted plain dose	Astellas Pharma	Approved	39
Venetoclax + Azacitidine + Cytarabine + Methotrexate + Hydrocortisone + Leucovorin + Dexamethasone + Vincristine + Doxorubicin + Dexrazoxane + Calaspargase Pegol + Erwinia asparaginase	AbbVie	Phase 1	36
Birabresib Dose 20 mg	Merck	Phase 1	21
Enteric-coated Mycophenolate sodium (EC-MPS)	Novartis	Phase 3	32
Enteric-coated Mycophenolate sodium (EC-MPS)	Novartis	Approved	43
Enteric-Coated Mycophenolate Sodium (EC-MPS)	Novartis	Approved	43
everolimus + cyclosporine + Prednison (continuous steroids)	Novartis	Phase 3	40
Enteric-coated Mycophenolate sodium (EC-MPS)	Novartis	Phase 3	40
AEB071	Novartis	Phase 1	29
Enteric-Coated Mycophenolate Sodium	Novartis	Phase 3	40
EC-MPS	Novartis	Phase 3	40
everolimus	Novartis	Phase 3	40
Prograf + Tacrolimus Hexal	Novartis	Approved	43
Mycophenolate Mofetil	Roche	Approved	43